Patents Assigned to National Institutes of Health
-
Publication number: 20080261211Abstract: Methods for identifying a subject at risk for developing AMD are disclosed, as are kits which can be used to practice the methods. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material, including polymorphisms in the BF, C2 and/or CFH genes. Microarrays and kits for use in these methods are also provided.Type: ApplicationFiled: February 13, 2007Publication date: October 23, 2008Applicants: Universtity of Iowa Research Foundation, The Trustees of Columbia University in The City of New York, National Institutes of Health Office of Technology TransferInventors: Rando L. Allikmets, Gregory S. Hageman, Michael C. Dean, Albert M. Gold
-
Publication number: 20080249026Abstract: The present invention relates to a peptide comprising the sequence R1-X1-X2-X3-X4-R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X1 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, and acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences. The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention.Type: ApplicationFiled: August 23, 2006Publication date: October 9, 2008Applicant: National Institutes of HealthInventors: David D. Roberts, Henry C. Krutzsch
-
Patent number: 7432067Abstract: Disclosed herein are novel nucleic acid and protein sequences that are essential to fertility. In particular, human Mater cDNA and protein sequences are provided. Functional MATER is required for female fertility; zygotes that arise from Mater null oocytes do not progress beyond the two-cell stage. Methods are described for detecting an autoimmune response to MATER in a subject by detecting autoantibodies that recognize an epitope of a MATER protein. Also provided are methods for diagnosis of infertility or reduced fertility by detecting presence of MATER protein autoantibodies in a subject. The disclosure also describes kits for detecting MATER autoantibodies comprising MATER protein.Type: GrantFiled: October 24, 2006Date of Patent: October 7, 2008Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services & The National Institutes of HealthInventors: Lawrence M. Nelson, Zhi-Bin Tong
-
Patent number: 7420032Abstract: Disclosed are methods for obtaining at least one epitope suitable for detecting the presence of an antibody against a tumor associated antigen of a cancer in a sample. Kits, assays, and substrates employing the epitopes of the present invention are disclosed. Also disclosed are epitopes of NY-ESO-1 and XAGE-1b and methods of using thereof.Type: GrantFiled: May 19, 2005Date of Patent: September 2, 2008Assignees: The Regents of the University of California, National Institutes of HealthInventor: Gang Zeng
-
Publication number: 20080194488Abstract: This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.Type: ApplicationFiled: April 14, 2008Publication date: August 14, 2008Applicants: National Institute of Health, Ramot at Tel-Aviv University Ltd.Inventors: Illana Gozes, Albert Pinhasov, Eliezer Giladi, Douglas E. Brenneman, Catherine Y. Spong
-
Patent number: 7407801Abstract: The present invention relates to nucleic acid molecules comprising certain truncated forms of the human cytomegalovirus (CMV) immediate-early enhancer-promoter, either alone or operably linked to transgenes of interest, including those encoding partially-deleted CFTR proteins. This invention further relates to vectors comprising these nucleic acid molecules and host cells transformed by such vectors. The nucleic acid molecules, vectors and transformed host cells of the present invention are useful for treating a variety of genetic, metabolic and acquired diseases, including inter alia cystic fibrosis (CF) airway disease.Type: GrantFiled: December 6, 2004Date of Patent: August 5, 2008Assignees: University of Iowa Research Foundation, National Institutes of Health (NIH)Inventors: Lynda S. Ostedgaard, Michael J. Welsh, Mark F. Stinski, John A. Chiorini
-
Publication number: 20080146501Abstract: Methods for identifying a subject at risk for developing AMD are disclosed. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material. Therapeutic compositions and methods are also provided for delaying the progression or onset of the development of AMD in a subject, including treating a subject having signs and/or symptoms of AMD or who has been diagnosed with AMD.Type: ApplicationFiled: February 13, 2007Publication date: June 19, 2008Applicants: University of Iowa Research Foundation, The Trustees of Columbia University in The City of New York, National Institutes of Health Office of Technology TransferInventors: Gregory S. Hageman, Rando Allikmets, Michael C. Dean, Albert M. Gold
-
Publication number: 20080138861Abstract: Recombinant respiratory syncytial virus (RSV) are provided in which expression of the second translational open reading frame encoded by the M2 gene (M2ORF2) is reduced or ablated to yield novel RSV vaccine candidates. Expression of M2 ORF2 is reduced or ablated by modifying a recombinant RSV genome or antigenome to incorporate a frame shift mutation, or one or more stop codons in M2 ORF2. Alternatively, M2 ORF2 is deleted in whole or in part to render the M2-2 protein partially or entirely non-functional or to disrupt its expression altogether. M2 ORF2 deletion and knock out mutants possess highly desirable phenotypic characteristics for vaccine development. These changes specify one or more desired phenotypic changes in the resulting virus or subviral particle. Vaccine candidates are generated that show a change in mRNA transcription, genomic or antigenomic RNA replication, viral growth characteristics, viral antigen expression, viral plaque size, and/or a change in cytopathogenicity.Type: ApplicationFiled: December 13, 2004Publication date: June 12, 2008Applicant: National Institutes of HealthInventors: Peter L. Collins, Brian R. Murphy, Alison Bermingham
-
Patent number: 7384908Abstract: This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.Type: GrantFiled: August 17, 2000Date of Patent: June 10, 2008Assignee: National Institute of HealthInventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Albert Pinhasov, Eliezer Giladi
-
Publication number: 20080069821Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: August 9, 2007Publication date: March 20, 2008Applicants: MedImmune Vaccines, Inc., The Government of the United States of America National Institutes of HealthInventors: Chin-Fen Yang, George Kemble, Kanta Subbarao, Brian Murphy
-
Publication number: 20080063345Abstract: A multi-photon microscope has an illumination source, an objective lens unit arranged in an optical path of the illumination source, a first light collection system arranged to collect a first portion of light emitted from a sample when the sample is illuminated by light from the illumination source, and a second light collection system arranged to collect a second portion of light emitted from the sample when the sample is illuminated by light from the illumination source. The first portion of light when collected by the first light collection system and the second portion of light when collected by the second light collection system, together provide a means of collecting as much light from as many angles as possible emanating from an emitting point source. This collection scheme has the potential to approach the total emission collection of light from an emitting point source depending on the optical properties of the sample being imaged.Type: ApplicationFiled: November 6, 2007Publication date: March 13, 2008Applicants: Health and Human Services, National Institutes of HealthInventors: Robert Balaban, Christian Combs, Jay Knutson
-
Patent number: 7320991Abstract: A number of thalidomide metabolites having superior anti-angiogenic properties have now been isolated and identified. In addition, thalidomide analogs that mimic the effects of the isolated and identified active thalidomide metabolites, and variations of such thalidomide analogs, have been developed. Such thalidomide analog compounds show enhanced potency in the inhibition of undesirable angiogenesis without the undesirable effects of administration of thalidomide.Type: GrantFiled: February 26, 2002Date of Patent: January 22, 2008Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of HealthInventors: William D. Figg, Kurt Eger, Uwe Teubert, Michael Weiss, Michael Guetschow, Thomas Hecker, Sunna Hauschildt
-
Publication number: 20070287753Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: ApplicationFiled: March 20, 2007Publication date: December 13, 2007Applicants: MOUNT SINAI SCHOOL OF MEDICINE, NATIONAL INSTITUTE OF HEALTH, YALE UNIVERSITY SCHOOL OF MEDICINEInventors: Dennis Charney, Sanjay Mathew, Husseini Manji, Carlos Zarate, John Krystal
-
Patent number: 7291494Abstract: The present invention is based on the discovery that a polypeptide containing the JAB subunit or the JAM domain has peptidase activity, e.g., isopeptidase activity. The present invention provides polypeptides and crystalline polypeptides containing the JAM domain and methods of using such polypeptides to screen for agents capable of affecting the peptidase activity of the polypeptides. The present invention also provides methods of using the JAM domain for rational drug design or identifying agents capable of affecting the peptidase activity of the JAM domain.Type: GrantFiled: January 14, 2002Date of Patent: November 6, 2007Assignees: California Institute of Technology, National Institutes of HealthInventors: Gregory Cope, Rati Verma, Lakshminarayanan Aravind, Eugene V. Koonin, Raymond Deshaies, Xavier Ambroggio
-
Diagnostic methods for pain sensitivity and chronicity and for tetrahydrobiopterin-related disorders
Publication number: 20070254288Abstract: Disclosed herein are methods for determining whether a subject possesses altered pain sensitivity an altered risk of developing acute or chronic pain, or diagnosing a tetrahydrobiopterin (BH4)-related disorder or a propensity thereto. These methods are based on the discovery of GCH1 and KCNS1 allelic variants that are associated with altered pain sensitivity and altered risk of developing acute or chronic pain, and the discovery that a GCH1 “pain protective haplotype” is associated with decreased upregulation of BH4 synthesis in treated leukocytes.Type: ApplicationFiled: October 20, 2006Publication date: November 1, 2007Applicants: The General Hospital Corporation, National Institutes of HealthInventors: Clifford Woolf, Michael Costigan, Mitchell Max, Inna Belfer, Steven Atlas, Albert Kingman, Tianxia Wu, David Goldman -
Patent number: 7267941Abstract: The present invention provides variants of cyanovirin-N and water-soluble polymer conjugates thereof. The cyanovirin-N of the invention are particularly suited for site-selective covalent attachment of one or more water soluble polymers, to provide polymer conjugates of cyanovirin-N variants exhibiting antiviral activity.Type: GrantFiled: December 18, 2003Date of Patent: September 11, 2007Assignees: The Government of the United States of America as represented by The Secretary of The Department of Health and Human Services, The National Institutes of Health, Nektar Therapeutics ALInventors: M. Elizabeth Snell, Michael J. Roberts, Toshiyuki Mori, Barry R. O'Keefe, Michael R. Boyd
-
Patent number: 7261896Abstract: The present invention provides a method for reducing stroke-related tissue damage by treating a mammal with E-selectin. Preferably, this treatment induces E-selectin tolerance in the mammal. Another aspect of the invention is a method for inducing E-selectin tolerance in a mammal through intranasal administration of E-selectin, preferably including booster administrations. The present methods are especially adapted for use in patients at increased risk of stroke or who may become at increased risk of stroke.Type: GrantFiled: May 23, 2001Date of Patent: August 28, 2007Assignee: United States of America as represented by the Secretary of the Department of Health and Human Services National Institutes of HealthInventors: John M. Hallenbeck, Hidetaka Takeda, Maria Spatz
-
Patent number: 7262018Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.Type: GrantFiled: September 14, 2004Date of Patent: August 28, 2007Assignee: National Institutes of HealthInventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
-
Publication number: 20070154971Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.Type: ApplicationFiled: March 7, 2007Publication date: July 5, 2007Applicant: National Institutes of HealthInventors: Harry Gelboin, Kristopher Krausz, Frank Gonzalez
-
Patent number: 7229963Abstract: A method of enhancing progenitor cell differentiation, including enhancing myogenesis, neurogenesis, and hematopoiesis, by contacting a progenitor cell with an effective amount of a deacetylase inhibitor (DI). The progenitor cell can be part of cell culture, such as a cell culture used for in vitro or in vivo analysis of progenitor cell differentiation, or can be part of an organsism, such as a human or other mammal. Contacting the progenitor cell with a DI can lead to enhancement of expression of terminal cell-type specific genes in the progenitor cell, such as enhancing expression of muscle-specific genes in myoblasts. Administering a DI to a subject also can provide some prophylactic or therapeutic effect for inhibiting, preventing, or treating associated with a degeneration or loss of tissue. The DI can be administered to a subject as part of a pharmaceutical composition.Type: GrantFiled: October 17, 2002Date of Patent: June 12, 2007Assignees: United States of America as represented by the Secretary of the Department of of Health Services, National Institutes of Health, The Salk Institute for Biological StudyInventors: Vittorio Sartorelli, Pier Lorenzo Puri